Miklos Schulz

No ORCID on file · 1 paper in corpus · active 2014

Study types

  • article 1

Condition tags

  • dysmenorrhea 1
article 2014
A first-in-human study of PDC31 (prostaglandin F2  receptor inhibitor) in primary dysmenorrhea
·doi:10.1093/humrep/deu205

STUDY QUESTION: What is the safe and pharmacodynamically active dose range for PDC31 (prostaglandin F2α receptor inhibitor) in patients with primary dysmenorrhea (PD)? SUMMARY ANSWER: The 1 mg/kg/h dose of PDC31 appears to be safe and poten…